{"id":"rifamycin-free-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL236921","moleculeType":"Small molecule","molecularWeight":"695.76"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifamycin-free regimens are designed for patients with TB strains resistant to rifamycin drugs (e.g., rifampicin) or for those who cannot tolerate rifamycins due to adverse effects or drug interactions. These regimens substitute rifamycins with other bactericidal or bacteriostatic agents that target mycobacterial cell wall synthesis, protein synthesis, or energy metabolism to achieve mycobacterial killing without relying on the rifamycin class.","oneSentence":"A tuberculosis treatment regimen that excludes rifamycin antibiotics, typically using alternative agents such as fluoroquinolones, bedaquiline, or linezolid to treat drug-resistant TB.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:01.197Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Drug-resistant tuberculosis (MDR-TB or XDR-TB) with rifamycin resistance or intolerance"},{"name":"Tuberculosis in patients with contraindications to rifamycin use"}]},"trialDetails":[{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":"Pulmonary Tuberculosis","enrollment":315},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT05588492","phase":"PHASE4","title":"The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-01-01","conditions":"Pulmonology","enrollment":500},{"nctId":"NCT03326050","phase":"EARLY_PHASE1","title":"Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-02","conditions":"Rhinoscleroma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rifamycin-free regimen","genericName":"Rifamycin-free regimen","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A tuberculosis treatment regimen that excludes rifamycin antibiotics, typically using alternative agents such as fluoroquinolones, bedaquiline, or linezolid to treat drug-resistant TB. Used for Drug-resistant tuberculosis (MDR-TB or XDR-TB) with rifamycin resistance or intolerance, Tuberculosis in patients with contraindications to rifamycin use.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}